Dr Feigal is currently a Partner and Head of the Biologics practice at global life sciences advisory firm, NDA Partners LLC, where she leads efforts in designing and executing product development and regulatory strategies in the areas of cell therapies, medical imaging, hematology and oncology. She is also adjunct faculty at the Sandra Day O'Connor College of Law, Arizona State University, where she teaches FDA drug law and medical research ethics and law. Dr Feigal was formerly Senior Vice President overseeing research and development with the California Institute of Regenerative Medicine, a research foundation working to accelerate development of new disease modifying treatments and cures for patients with chronic diseases; Executive Medical Director, Global Development at US biotech company Amgen Inc (NASDAQ: AMGN); Vice President of Clinical Sciences at the Translational Genomics Research Institute, and directed the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. Dr Feigal serves as a Board member for Xencor Inc (NASDAQ: XNCR) a biotechnology company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases. She is also a Director of NextCure (NASDAQ: NXTC) a clinical-stage biotechnology company developing new immunotherapies to treat cancer.
